Skip to main content
VulnerabilityPublished Updated

CVE-2026-52866: Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) · Missing Authorization

Affects Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT)Source CVE Database V5

0
Compare

Not known to be exploited · CVSS 6.5 Medium.

Data as of 1 Nov 2026, 22:58 UTC

CVSS 3.1 base score
6.5Medium
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.3% chance of exploitation in 30 days – higher than 28% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 18 Jun 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 1 Nov 2026.

What to do

Affected software

ProductAffectedFixed in
Apollo PharmacyBlood Glucose Monitoring System (Model No. APG-01 BT)Affected
  • =0x0110_v1.1.0
Fixed in–

AI-suggested

Users should monitor vendor advisories for updates. As the device is not a cloud service, remediation depends on vendor-provided firmware updates. Until a fix is released, limiting physical proximity to trusted users and devices may reduce risk.

Description

An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.

References

Community reviews

Loading reviews…